| Aug 7 |
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
|
| Jul 30 |
Bullish Larimar Therapeutics Insiders Loaded Up On US$540.7k Of Stock
|
| Jul 15 |
Larimar Therapeutics: More Data Still Needed
|
| May 31 |
Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed
|
| May 30 |
Larimar's Friedreich's ataxia asset nomlabofusp chosen for FDA accelerated program
|
| May 30 |
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
|
| May 21 |
Biggest stock movers today: ZIM, XPEV, PANW, GOTU, and more
|
| May 20 |
Larimar stock rallies 24% on FDA removal of partial clinical hold
|
| May 20 |
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
|
